<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">914</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2023-13-3-51-62</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Intra-tumoral molecular heterogeneity of grade 3 astrocytomas and oligodendrogliomas and its significance in disease prognosis</article-title><trans-title-group xml:lang="ru"><trans-title>Внутриопухолевая молекулярная гетерогенность астроцитом и олигодендроглиом grade 3 и ее значение в прогнозе заболевания</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3223-4584</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikitin</surname><given-names>P. V.</given-names></name><name xml:lang="ru"><surname>Никитин</surname><given-names>П. В.</given-names></name></name-alternatives><address><country country="US">United States</country></address><bio xml:lang="en"><p><italic>4849 Calhoun Road, Houston 77004, Texas</italic></p></bio><bio xml:lang="ru"><p><italic>4849 Калхун-роуд, Хьюстон 77004</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2337-6495</contrib-id><name-alternatives><name xml:lang="en"><surname>Belyaev</surname><given-names>A. Yu.</given-names></name><name xml:lang="ru"><surname>Беляев</surname><given-names>А. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Sergey A. Lukyanov</bold></p><p><italic>16, 4<sup>th</sup> Tverskaya-Yamskaya, Moscow 12504</italic>7</p></bio><bio xml:lang="ru"><p><bold>Артем Юрьевич Беляев </bold></p><p><italic>125047 Москва, 4-я Тверская-Ямская, 16</italic></p></bio><email>belyaev@nsi.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9962-0909</contrib-id><name-alternatives><name xml:lang="en"><surname>Musina</surname><given-names>G. R.</given-names></name><name xml:lang="ru"><surname>Мусина</surname><given-names>Г. Р.</given-names></name></name-alternatives><address><country country="US">United States</country></address><bio xml:lang="en"><p><italic>3; 1 Baylor Plaza, Houston 77030, Texas</italic></p></bio><bio xml:lang="ru"><p><italic>1 Бэйлор Плаза, Хьюстон 77030</italic></p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7651-4214</contrib-id><name-alternatives><name xml:lang="en"><surname>Kobyakov</surname><given-names>G. L.</given-names></name><name xml:lang="ru"><surname>Кобяков</surname><given-names>Г. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>16, 4<sup>th</sup> Tverskaya-Yamskaya, Moscow 12504</italic>7</p></bio><bio xml:lang="ru"><p><italic>125047 Москва, 4-я Тверская-Ямская, 16</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4480-0275</contrib-id><name-alternatives><name xml:lang="en"><surname>Pronin</surname><given-names>I. N.</given-names></name><name xml:lang="ru"><surname>Пронин</surname><given-names>И. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>16, 4<sup>th</sup> Tverskaya-Yamskaya, Moscow 12504</italic>7</p></bio><bio xml:lang="ru"><p><italic>125047 Москва, 4-я Тверская-Ямская, 16</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8924-7346</contrib-id><name-alternatives><name xml:lang="en"><surname>Usachev</surname><given-names>D. Yu.</given-names></name><name xml:lang="ru"><surname>Усачев</surname><given-names>Д. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>16, 4<sup>th</sup> Tverskaya-Yamskaya, Moscow 12504</italic>7</p></bio><bio xml:lang="ru"><p><italic>125047 Москва, 4-я Тверская-Ямская, 16</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">University of Houston</institution></aff><aff><institution xml:lang="ru">Хьюстонский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.N. Burdenko National Medical Research Center of Neurosurgery, of the Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАУ «Национальный медицинский исследовательский центр нейрохирургии им. Н.Н. Бурденко»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Baylor Medical College</institution></aff><aff><institution xml:lang="ru">Медицинский колледж Бэйлора</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-12-12" publication-format="electronic"><day>12</day><month>12</month><year>2023</year></pub-date><volume>13</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>51</fpage><lpage>62</lpage><history><date date-type="received" iso-8601-date="2023-12-11"><day>11</day><month>12</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-12-11"><day>11</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Nikitin P.V., Belyaev A.Y., Musina G.R., Kobyakov G.L., Pronin I.N., Usachev D.Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Никитин П.В., Беляев А.Ю., Мусина Г.Р., Кобяков Г.Л., Пронин И.Н., Усачев Д.Ю.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Nikitin P.V., Belyaev A.Y., Musina G.R., Kobyakov G.L., Pronin I.N., Usachev D.Y.</copyright-holder><copyright-holder xml:lang="ru">Никитин П.В., Беляев А.Ю., Мусина Г.Р., Кобяков Г.Л., Пронин И.Н., Усачев Д.Ю.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/914">https://ogsh.abvpress.ru/jour/article/view/914</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Malignant brain tumors, such as anaplastic astrocytomas and anaplastic oligodendrogliomas grade 3, are characterized by high aggressiveness and pose a serious clinical problem. This study focuses on assessing intratumoral heterogeneity in anaplastic astrocytomas and anaplastic oligodendrogliomas and its impact on disease prognosis.</p><p><bold>Aim. </bold>To study characteristics of intratumoral heterogeneity, in particular such morphological criteria as necrosis, vascular proliferation, mitoses, and mutations in the most significant for glioma progression genes in the groups of grade III astrocytomas and oligodendrogliomas, as well as analysis of prognostic significance of these parameters.</p><p><bold>Materials</bold><bold> </bold><bold>and</bold><bold> </bold><bold>methods.</bold><bold> </bold>The study included 389 patients with IDH-mutant astrocytomas and 200 patients with oligodendrogliomas. The mean Ki-67 labeling index of astrocytomas was 12.78 %, while that of oligodendrogliomas was 8.54 %.</p><p><bold>Results. </bold>The presence of vascular proliferation, necrosis, of more than 20 % of the area of the specimen occupied by sarcomatous-like areas and the number of mitoses significantly affected not only disease-free survival but also overall survival of patients. In the clinical setting, mutations in the TERT promoter gene, amplification and mutation of the EGFR gene, deletion of the CDKN2A gene, and TP53 gene had a significant negative impact on recurrence-free and overall survival.</p><p><bold>Conclusion. </bold>The results of single-cell RNA sequencing showed additional factors, including sarcomatous-like areas, as well as TERT, EGFR, CDKN2A and TP53 mutations, in the progression of the tumors under consideration and in ensuring an increase in their malignant potential.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>злокачественные опухоли головного мозга, такие как астроцитомы и олигодендроглиомы grade 3 (анапластические астроцитомы и анапластические олигодендроглиомы), характеризуются высокой агрессивностью и представляют собой серьезную клиническую проблему. Данная работа посвящена оценке внутриопухолевой гетерогенности этих новообразований и ее влияния на прогноз заболевания.</p><p><bold>Цель исследования </bold>– изучение свойств внутриопухолевой гетерогенности, в частности морфологических критериев, таких как некрозы, сосудистая пролиферация, митозы, и мутаций в наиболее значимых для прогрессирования глиом генах в группах астроцитом и олигодендроглиом grade 3, а также анализ прогностической значимости этих показателей.</p><p><bold>Материалы и методы.</bold><bold> </bold>В исследование включены 389 пациентов с <italic>IDH</italic>-мутантными анапластическими астроцитомами и 200 пациентов с анапластическими олигодендроглиомами. средний индекс мечения Ki-67 для астроцитом составил 12,78 %, для олигодендроглиом – 8,54 %.</p><p><bold>Результаты. </bold>Наличие сосудистой пролиферации, некроза, более 20 % площади препарата, занятой саркомоподобными участками, а также количество митозов существенно влияли на показатели не только безрецидивной, но и общей выживаемости пациентов. В клинических условиях мутации в промоторе гена <italic>TERT</italic>, амплификация и мутация гена <italic>EGFR</italic>, делеция генов <italic>CDKN2A </italic>и <italic>TP53 </italic>оказывали значительное негативное влияние на эти показатели.</p><p><bold>Заключение. </bold>по результатам single-cell секвенирования РНК выявлены дополнительные факторы прогрессирования рассматриваемых опухолей и повышения их злокачественного потенциала, в том числе наличие саркомоподобных участков, а также мутаций в генах <italic>TERT</italic>, <italic>EGFR</italic>, <italic>CDKN2A </italic>и <italic>TP53</italic>.</p></trans-abstract><kwd-group xml:lang="en"><kwd>astrocytoma grade 3</kwd><kwd>oligodendroglioma grade 3</kwd><kwd>intra-tumoral heterogeneity</kwd><kwd>overall survival</kwd><kwd>progressionfree survival</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>астроцитома grade 3</kwd><kwd>олигодендроглиома grade 3</kwd><kwd>внутриопухолевая гетерогенность</kwd><kwd>общая выживаемость</kwd><kwd>безрецидивная выживаемость</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Louis D.N., Perry A., Reifenberger G., von Deimling A. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica 2016;131(6):803–20. DOI: 10.1007/s00401-016-1545-1</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Cardiff R.D., Miller C.H., Munn R.J. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harbor Protocols 2014;2014(6):655–8. DOI: 10.1101/pdb.prot073411</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nikitin P.V., Musina G.R., Pekov S.I. et al. Cell-population dynamics in diffuse gliomas during gliomagenesis and its impact on patient survival. Cancers 2022;15(1):145–64. DOI: 10.3390/cancers15010145</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ravi R.K., Walton K., Khosroheidari M. MiSeq: a next generation sequencing platform for genomic analysis. Methods Mol Biol 2018;1706:223–32. DOI: 10.1007/978-1-4939-7471-9_12</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ceccarelli M., Barthel F.P., Malta T.M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016;164(3):550–63. DOI: 10.1016/j.cell.2015.12.028</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Griveau A., Seano G., Shelton S.J. et al. A Glial signature and Wnt7 signaling regulate glioma-vascular interactions and tumor microenvironment. Cancer Cell 2018;33(5):874–89.e7. DOI: 10.1016/j.ccell.2018.03.020</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Venteicher A.S., Tirosh I., Hebert C. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by singlecell RNA-seq. Science 2017;355(6332):eaai8478. DOI: 10.1126/science.aai8478</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Inoue S., Li W.Y., Tseng A. et al. Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell 2016;30(2):337–48. DOI: 10.1016/j.ccell.2016.05.018</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Berzero G., Di Stefano A.L., Ronchi S. et al. IDH-wildtype lowergrade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro-Oncology 2021;23(6):955–66. DOI: 10.1093/neuonc/noaa258</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Shirahata M., Ono T., Stichel Det al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica 2018;136(1):153–66. DOI: 10.1007/s00401-018-1849-4</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Galbraith K., Snuderl M. Molecular pathology of gliomas. Surg Pathol Clin 2021;14(3):379–86. DOI: 10.1016/j.path.2021.05.003</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Xu W., Yang X., Hu X., Li S. Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing. Int J Mol Med 2014;34(1):53–60. DOI: 10.3892/ijmm.2014.1756</mixed-citation></ref></ref-list></back></article>
